title: Involvement of protein kinase C in the adaptive changes of cholinergic neurons to sympathetic denervation in the guinea pig myenteric plexus.
abstract: Supersensitivity to muscarinic, kappa- and mu-opioid agents modulating cholinergic neurons in the guinea pig colon develops after chronic sympathetic denervation. A possible role for protein kinase C (PKC) in contributing to development of these sensitivity changes was investigated. The PKC activator, phorbol-12-myristate-13-acetate (PMA), enhanced acetylcholine (ACh) overflow in preparations obtained from normal animals. The facilitatory effect of PMA was significantly reduced after prolonged exposure to the phorbol ester and by the PKC inhibitors, chelerythrine and calphostin C. Subsensitivity to the facilitatory effect of PMA developed after chronic sympathetic denervation. In this experimental condition, immunoblot analysis revealed reduced levels of PKC in myenteric plexus synaptosomes. The facilitatory effect of the muscarininc antagonist, scopolamine, on ACh overflow was significantly reduced by the phospolipase C (PLC) inhibitor, U73122, chelerythrine and calphostin C, both in normal and denervated animals. However, in both experimental groups, PLC antagonists and PKC antagonists did not affect the inhibitory effect of the muscarinic agonist, oxotremorine-M on ACh overflow. The inhibitory effects of U69593 (kappa-opioid receptor agonist) and DAMGO (mu-opioid receptor agonist) on ACh overflow significantly increased in the presence of U73122, chelerythrine and calphostin C in preparations obtained from normal animals, but not in those obtained from sympathetically denervated animals. These results indicate that activation of PKC enhances ACh release in the myenteric plexus of the guinea pig colon. At this level, chronic sympathetic denervation entails a reduced efficiency of the enzyme. In addition, PKC is involved in the inhibitory modulation of ACh release mediated by muscarinic-, kappa- and mu-opioid receptors, although with different modalities. Muscarinic receptors inhibit PKC activity, whereas kappa- and mu-opioid receptors increase PKC activity. Both the inhibitory and the facilitatory effect on PKC involve modulation of PLC activity. The possibility that the change in PKC activity represents one of the biochemical mechanisms at the basis of development of sensitivity changes to opioid and muscarinic agents after chronic sympathetic denervation is discussed.
authors.affiliation: Clinical and Applied Pharmacology Centre, University of Insubria and University of Pavia, I-21100 Varese, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Zanetti
authors.forename: Cristina
authors.initials: C
authors.lastname: Giaroni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Vanti
authors.forename: Luca
authors.initials: L
authors.lastname: Canciani
authors.forename: Daniela
authors.initials: D
authors.lastname: Giuliani
authors.forename: Sergio
authors.initials: S
authors.lastname: Lecchini
authors.forename: Gianmario
authors.initials: G
authors.lastname: Frigo
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000222:Adaptation, Physiological / Q000502:physiology*; D000470:Alkaloids; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D053119:Benzophenanthridines; D003106:Colon / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006168:Guinea Pigs; D015151:Immunoblotting; D066298:In Vitro Techniques; D018721:Muscarinic Agonists / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009197:Myenteric Plexus / Q000502:physiology*; D009281:Naphthalenes / Q000494:pharmacology; D009474:Neurons / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology; D010275:Parasympathetic Nervous System / Q000166:cytology* / Q000502:physiology*; D010617:Phenanthridines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D017473:Receptors, Opioid, kappa / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000819:agonists; D012601:Scopolamine / Q000494:pharmacology; D013562:Sympathectomy; D014404:Tubulin / Q000378:metabolism
chemical_list: D000470:Alkaloids; D000701:Analgesics, Opioid; D053119:Benzophenanthridines; D004791:Enzyme Inhibitors; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D009281:Naphthalenes; D010617:Phenanthridines; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D014404:Tubulin; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D010095:Oxotremorine; D012601:Scopolamine; C016299:chelerythrine; D011493:Protein Kinase C; C058819:calphostin C; D000109:Acetylcholine